Seeking Alpha

Leonard Yaffe's  Instablog

Leonard Yaffe
Send Message
I am an MD by background who runs a healthcare hedge fund. I worked as a sell-side medical analyst for 20 years, covering pharmaceuticals, medical devices, PBMs and drug distributors.
  • GILD: Sovaldi Prescription Trends Remain Strong 1 comment
    Feb 7, 2014 1:54 PM | about stocks: GILD

    The latest week prescription data suggests that Sovaldi now accounts for 84% of new prescriptions in the combined PI+NS5B classes for Hepatitis C treatment. This exceeds all forecasts; furthermore, I believe that Wall Street is underestimating the current annualized dollar run rate. Each weekly one-month prescription is worth approximately $28,000 (I discount it to $22,000). However, the standard course of therapy is for 3 months. Therefore, the difference between new prescriptions (NRx) and total prescriptions (TRx) will continue to diverge as more people initiate therapy and get their refills. Said another way, if new weekly prescriptions did not increase from the current 2500 level, total prescriptions, now at 3200, would rise over time to close to 5000. I expect NRx to increase sequentially by 50 on average, implying a much higher run rate as the year progresses.

    Although GILD's stock price will be driven by its Hepatitis C-related revenues in 2014, I remain impressed with its pipeline in anti-infectives, oncology and fibrosis.

    Len

    Disclosure: I am long GILD.

    Themes: Pharmaceuticals Stocks: GILD
Back To Leonard Yaffe's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (1)
Track new comments
  • JAC92651
    , contributor
    Comments (76) | Send Message
     
    thanks for the great article. I look forward to a blow out before the year is over.
    9 Feb 2014, 03:48 PM Reply Like
Full index of posts »
Latest Followers

StockTalks

  • $GILD Gilead Anthem deal, if no patient exclusions (ie fibrosis stage), is another example of trading volume for price. Win-win. BUY GILD
    Jan 8, 2015
  • Is There A New Reality To The Drug Industry? http://seekingalpha.com/a/1nid5
    Dec 23, 2014
  • Update: News On Gilead From The California Technology Assessment Forum $GILD http://seekingalpha.com/a/1nbxr
    Dec 19, 2014
More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.